Ingrezza FDA Approval History
FDA Approved: Yes (First approved April 11, 2017)
Brand name: Ingrezza
Generic name: valbenazine
Dosage form: Capsules
Company: Neurocrine Biosciences, Inc.
Treatment for: Tardive Dyskinesia
Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor for the treatment of tardive dyskinesia.
Development timeline for Ingrezza
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.